Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · IEX Real-Time Price · USD
27.18
+0.75 (2.82%)
May 20, 2024, 11:52 AM EDT - Market open
Cartesian Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for RNAC stock have an average target of 45, with a low estimate of 39 and a high estimate of 54. The average target predicts an increase of 65.59% from the current stock price of 27.18.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RNAC stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|
| Strong Buy | 1 | 2 | 2 |
| Buy | 0 | 1 | 1 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $54 | Strong Buy | Reiterates | $54 | +98.71% | May 9, 2024 |
| Needham | Needham | Strong Buy Reiterates $42 | Strong Buy | Reiterates | $42 | +54.55% | May 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $54 → $2 | Strong Buy | Maintains | $54 → $2 | -92.64% | Apr 23, 2024 |
| Leerink Partners | Leerink Partners | Buy Initiates $39 | Buy | Initiates | $39 | +43.51% | Apr 23, 2024 |
| Needham | Needham | Strong Buy Reiterates $42 | Strong Buy | Reiterates | $42 | +54.55% | Apr 10, 2024 |
Financial Forecast
Revenue This Year
34.17M
from 26.00M
Increased by 31.40%
Revenue Next Year
50.74M
from 34.17M
Increased by 48.50%
EPS This Year
-3.98
from -49.80
EPS Next Year
-1.53
from -3.98
Revenue Forecast
| Revenue | 2024 | 2025 | 2027 | 2028 |
|---|---|---|---|---|
| High | 49.4M | 52.2M | 30.5M | 86.1M |
| Avg | 34.2M | 50.7M | 14.8M | 49.6M |
| Low | 19.6M | 48.8M | n/a | 15.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2027 | 2028 |
|---|---|---|---|---|
| High | 89.8% | 52.9% | -40.0% | 482.2% |
| Avg | 31.4% | 48.5% | -70.9% | 235.5% |
| Low | -24.6% | 42.7% | - | 1.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2027 | 2028 |
|---|---|---|---|---|
| High | -1.58 | -1.58 | -7.46 | -7.64 |
| Avg | -3.98 | -1.53 | -7.24 | -7.43 |
| Low | -6.17 | -1.47 | -6.96 | -7.13 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | - | - |
| Avg | - | - | - | - |
| Low | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.